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Abstract
Purpose The increasing trend of chest CT utilization during the COVID-19 pandemic necessitates novel protocols with reduced
dose and maintained diagnostic accuracy. We aimed to investigate the diagnostic accuracy of 30-mAs chest CT protocol in
comparison with a 150-mAs standard-dose routine protocol for imaging of COVID-19 pneumonia.
Methods Upon IRB approval, consecutive laboratory-confirmed positive COVID-19 patients aged 50 years or older who were
referred for chest CT scan and had same-day normal CXR were invited to participate in this prospective study. First, a standard-
dose chest CT scan (150 mAs) was performed. Only if typical COVID-19 pneumonia features were identified, then a low-dose
CT (30 mAs) was done immediately. Diagnostic accuracy of low-dose and standard-dose CT in the detection of typical COVID-
19 pneumonia features were compared.
Results Twenty patients with a mean age of 64.20 ± 13.8 were enrolled in the study. There was excellent intrareader agreement in
detecting typical findings of COVID-19 pneumonia between low-dose and standard-dose (intraclass correlation coefficient
[ICC] = 0.98–0.99, P values < 0.001 all readers). The mean effective dose values in standard- and low-dose groups were 6.60
± 1.47 and 1.80 ± 0.42mSv, respectively. Also, absolute cancer risk per mean cumulative effective dose values obtained from the
standard- and low-dose CT examinations were 2.71 × 10−4 and 0.74 × 10−4, respectively.
Conclusions According to our study, it was found that proposed low-dose CT chest protocol is reliable in detecting COVID-19
pneumonia in daily practice with significant reduction in radiation dose and estimated cancer risk.
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Introduction
The outbreak of Coronavirus Disease 19 (COVID-19) was
first reported in Wuhan, China, in December 2019. Shortly
after, the disease was extended as a pandemic affecting 203
countries and territories with the number of confirmed cases
surpassing 17 million globally as of July 31, 2020 [1]. The
current rapid spread and surge in deaths during the COVID-19
pandemic can be altered by early detection, timely interven-
tion, and public health measurements [2].
Although real-time reverse transcriptase polymerase chain
reaction (RT-PCR) remains the standard diagnostic reference
of COVID-19, many limitations such as high false-negative
rate, limited availability, and delay in confirmation may exist
[3]. More specifically, the World Health Organization and
Centers for Disease Control recommends viral testing (includ-
ing PCR) as the method for the identification and laboratory
confirmation of COVID-19 cases. Despite high analytical
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sensitivity and near-perfect specificity, test sensitivity in clin-
ical practice may be adversely affected by some variables,
including adequacy of specimen, specimen type, specimen
handling, and stage of infection in which the specimen is
acquired [4, 5]. False-negative RT-PCR tests have been re-
ported in patients with CT findings of COVID-19 who even-
tually tested positive with serial sampling [6]. On the other
hand, CT abnormalities might predate RT-PCR positivity in
symptomatic patients and in those without symptoms who
subsequently test positive by RT-PCR [7].
Chest X-ray (CXR) is not a sensitive tool to detect viral
pneumonia [8]. However, it has been shown that chest com-
puted tomography (CT) scan plays a key role in the detection
of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pneumonia [9–11]. More recent studies have
suggested that CT scan not only demonstrates the course of
the disease and the severity of involvement but also is able to
predict the prognosis [12–14]. Although current guidelines do
not recommend CT as a screening tool [15], the widespread
availability, high sensitivity, and short test-to-result time in-
terval suggest that many cases with suspicious clinical or
equivocal laboratory data will benefit from chest CT scan
for the diagnosis of COVID-19 pneumonia, particularly where
RT-PCR kits are limited or not easily accessible. Patients at
higher risk for complication, those with comorbidities, not
responding to supportive treatment, and presenting with acute
clinical deterioration are among the groups that benefit imag-
ing the most [16].
The increasing trend of chest CT scan utilization during the
COVID-19 pandemic raises the concern about the radiation
burden of the population [17], both in patients and health care
workers. It is widely accepted that ionizing radiation increases
the lifetime likelihood of developing cancer [18]. Most recent-
ly, Sakane et al., based on a study on 209 patients, concluded
that standard-dose chest CT results in chromosome aberra-
tions and DNA double-strand break, while no detrimental ef-
fect on human DNA by low-dose chest CT was detected [19].
Accordingly, the principle of ALARA (as low as rea-
sonably achievable) suggested by the International
Commission of Radiological Protection (ICRP) should
be followed in the daily practice of radiology, even in
the setting of pandemic events [20].
Multiple prior studies have suggested that obtaining a low-
dose chest CT scan by applying a reduced tube current results
in reliable sensitivity compared with the standard-dose CT
protocols in detecting intrathoracic pathologies, such as pul-
monary nodules, lung masses, or parenchymal abnormalities.
For example, Zhu et al. concluded that low-dose (40 or
25 mAs) helical chest CT protocol produced diagnostic image
quality, thus optimally protecting patients from radiation ex-
posure [21]. Kubo et al. reported that application of 50mAs as
tube current for the routine chest CT has comparable diagnos-
tic performance as standard-dose of 150 mAs [22].
A recent study by Tofighi et al. has discussed the applica-
tion of low-dose CT in COVID-19 pneumonia and stated that
low-dose and ultralow-dose CT have a comparable efficacy in
the detection of ground glass and consolidative opacities.
They have suggested comparison of low-dose and conven-
tional protocol in early stages of the disease, because in inter-
mediate and advanced stages, the low-dose CT protocol will
provide adequate image quality and diagnostic accuracy [23].
More recently published studies on applying low radiation
dose chest CT scan in COVID-19 pneumonia have suggested
acceptable diagnostic accuracy [17, 24], although they are all
non-comparison studies. A statistically more advanced study
designed based on an internal control and head-to-head com-
parison of pulmonary findings in COVID-19 in low- and
conventional-dose CT has not been performed yet.
In this prospective study, we aimed to study the diagnostic
accuracy of a 30-mAs chest CT compared with standard-dose
(150 mAs) as the routine protocol for imaging of COVID-19
in patients with initial normal CXR. It has been hypothesized
that a low-dose chest CT protocol would yield into a compa-
rable diagnostic accuracy compared with standard protocol in
the detection of COVID-19 pneumonia.
Methods
Patient selection
The study was performed between March 15 and 31, 2020, at
the department of radiology in our institution. A total of 63
consecutive patients aged 50 years or older who were referred
for a non-contrast chest CT scan and had same-day normal
chest radiographs were invited to participate in this prospec-
tive study. Patients younger than 50 years old were excluded,
as cancer risk related to ionizing radiation exposure is higher
in younger population [22]. All patients were symptomatic
with positive RT-PCR for SARS-CoV-2 infection at their first
imaging referral for the evaluation of extent and severity of
COVID-19 pneumonia. The institutional review board ap-
proved the research protocol, and written informed consent
was obtained from all participants.
For all patients, standard-dose chest CT scan was
performed as the first step. Only if typical COVID-19
pneumonia features on the standard-protocol CT [25]
were identified by the radiologist present in the work-
station, the low-dose CT was done immediately after
that, without moving the patient on the CT table.
Ultimately, 20 patients were enrolled in the study. The
research ethics board approved our research protocol
(approval ID: IR.KAUMS.REC.1398.053), and written
informed consent was obtained from all the patients
who agreed to enroll in this study.
Emerg Radiol
CT protocols
CT chest was acquired using a 16-detector CT scanner
(Alexion TSX-034A, Toshiba, Japan). All patients were ex-
amined in supine position. After obtaining a routine scout
view, two successive helical CT scans from the base of the
neck to the liver dome with a fixed tube voltage of 120 kVp
and tube currents of 150 mAs (standard protocol) and then 30
mAs (low-dose protocol) were performed. From the raw data
of each acquisition, contiguous 3-mm-thickness slices were
reconstructed based on lung construction algorithm. The pitch
factor was 1 for both protocols. No patient received intrave-
nous contrast material. Results of the CT examination were
immediately interpreted and reported to the referring clinician,
who integrated the results into the clinical case management
decision.
Image analysis
There were 40 series (20 standard-dose and 20 low-dose) of
chest CT scans, coded randomly and anonymized by a radi-
ologist who was not involved in reading the examinations.
The images were read independently by three radiologists:
reader A (H.R with 5-year experience), reader B (SMH. T
with 7-year experience), and reader C (HR. T with 15-year
experience). The patients’ name, date of performing CT scan,
and image acquisition data (including radiation dose) were
masked to blind the readers. The readers were also blinded
to the CXRs and RT-PCR results.
In order to assess the clarity and visibility of typical CT
findings of COVID-19 pneumonia on CT scan, the presence
or absence of them was recorded using a 3-point CT finding
scale (0, definitely absent; 1, equivocal; 2, definitely present).
The readers were asked to interpret each lobe of the lungs
separately, right upper lobe (RUL), right middle lobe
(RML), right lower lobe (RLL), left upper lobe (LUL), and
left lower lobe (LLL), and provide one score for it. If one or
more typical finding(s) of COVID-19 pneumonia was found,
a score of 2 would be given to the concerned lobe, and a score
of 1 is assigned when the lesion(s) was unclear (equivocal).
Score 0 indicates normal lung parenchyma or no lesion typical
for COVID-19 pneumonia. The scores were combined for all
five lobes to provide a summed total score ranging from 0 to
10. All CT images were viewed with both lung window
(width, 1600 HU; level, − 550 HU) and mediastinal window
(width, 400 HU; level, 40 HU) settings.
Any of the followings were considered a typical finding for
COVID-19 pneumonia based on the Radiological Society of
North America Expert Consensus Statement [25]: peripheral
ground glass opacity (GGO) with or without consolidation or
visible intralobular lines (crazy paving), multifocal GGO of
rounded morphology with or without consolidation or visible
intralobular lines (crazy paving), and reverse halo sign or
other findings of organizing pneumonia. The readers also
assessed the images on mediastinal window settings for eval-
uation of mediastinal/hilar lymphadenopathy or pleural/
pericardial effusion.
Statistical analysis
To evaluate the inter-reader agreement among the three radi-
ologists for each lobe, kappa (ĸ) test was used. Intraclass co-
efficient correlation (ICC) was used to assess the inter-reader
agreement by comparing the total score in both low-dose and
standard-dose. To evaluate the intrareader agreement between
the low-dose and standard-dose, ĸ values were obtained for
each lobe and each radiologist. ICC was then used to assess
the intrareader agreement in evaluation of total lung score
between the low-dose and standard-dose.
All ĸ and ICC values were interpreted as proposed in the
literature [26, 27]. A ĸ value lower than 0.20 indicated poor
agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate
agreement; 0.61–0.80, good agreement; and 0.81–1.00, excel-
lent agreement. An ICC below 0.50 indicated poor agreement,
between 0.50 and 0.75 moderate, between 0.75 and 0.90
good, and above 0.90 excellent. The results were considered
statistically significant when P value < 0.05.
Effective radiation dose and cancer risk estimation
The effective dose values (mSv) of chest CT scan examina-
tions were calculated by multiplying dose-length product
(DLP) with conversion coefficients (0.016 mSv/mGy∙cm)
presented by Huda et al. [28], with DLP values extracted from
the patients’ information.
In the present study, the cancer absolute risks follow-
ing standard-dose and low-dose CT scan examinations
were estimated in accordance with the risk model pre-
sented in ICRP Publication 103 [29]. Absolute risk is
defined as the probability that a person of disease-free
at a specific age will develop the cancer disease later
following radiation exposure to a risk factor. To calcu-
late the cancer risk, mean effective dose values obtained
from standard-dose and low-dose CT scan examinations
were multiplied by the risk coefficient (0.041 Sv−1).
Results
A total of 20 patients were enrolled in the study, consisting of
7 females and 13 males, aged between 50 and 99 years (mean




The mean total lung scores calculated for readers A, B, and C
in low-dose CT protocol were 5.60 ± 3.2, 6.40 ± 3.0, and 6.20
± 2.6, respectively. The total scores for readers A, B, and C in
standard-dose CT protocol were 5.80 ± 3.2, 6.45 ± 3.0, and
6.20 ± 2.7, respectively. No chest CT was reported as normal
without lung parenchymal abnormalities by the three readers.
Inter-reader agreement was assessed for both low-dose and
standard-dose in each lobe using ĸ value (Table 1). Inter-
reader agreements in evaluation of total involvement score
were assessed for both low-dose and standard-dose measure-
ments (Table 1). There is excellent inter-reader agreement
based on ICC values in both low-dose and standard-dose mea-
surements, 0.84 and 0.81, respectively.
Intrareader agreements were assessed between low-dose
and standard-dose using ĸ, and P values were calculated for
each lobe (Table 2). The highest agreements between low-
dose and standard-dose were seen in RUL, RML, and LUL
with all ĸ values ranging from 0.91 to 1.00 among all readers
(P value < 0.001 all) (Fig. 1a,b). The lowest agreement was
seen in RLLwith ĸ ranging from 0.67 to 0.86 (P value < 0.001
all) (Figs. 2a,b and 3a,b).
ICC was used to assess intrareader agreement be-
tween the low-dose and standard-dose in calculation of
the total score of lung involvement (Table 2). All
readers have high ICC (0.98–0.99) with a statistically
significant confidence interval in calculation of total
lung score between low-dose and standard-dose (P
values < 0.001 for all readers).
Table 1 Inter-reader agreement
for both standard- and low-dose
protocols in evaluation of each
lobe and total lung score
Lobe Kappa (ĸ) P value for ĸ ICC [confidence interval]
total lung score
P value for ICC
Standard-dose RUL 0.63 < 0.001 0.81 [0.66–0.91] < 0.001
RML 0.45 < 0.001
RLL 0.45 < 0.001
LUL 0.53 < 0.001
LLL 0.67 < 0.001
Low-dose RUL 0.54 < 0.001 0.84 [0.70–0.93] < 0.001
RML 0.46 < 0.001
RLL 0.51 < 0.001
LUL 0.54 < 0.001
LLL 0.67 < 0.001
RUL right upper lobe, RML right middle lobe, RLL right lower lobe, LUL left upper lobe, LLL left lower lobe, ICC
intraclass correlation coefficient
Table 2 Intrareader agreement
between low-dose and standard-
dose for each reader in evaluation
of each lobe and total lungs score
Lobe Kappa (ĸ) P value for ĸ ICC [confidence interval]
total lung score
P value for ICC
Reader A RUL 1.00 < 0.001 0.98 [0.96–0.99] < 0.001
RML 0.91 < 0.001
RLL 0.86 < 0.001
LUL 1.00 < 0.001
LLL 0.80 < 0.001
Reader B RUL 1.00 < 0.001 0.99 [0.98–0.99] < 0.001
RML 1.00 < 0.001
RLL 0.81 < 0.001
LUL 1.00 < 0.001
LLL 0.73 < 0.001
Reader C RUL 0.81 < 0.001 0.98 [0.95–0.99] < 0.001
RML 1.00 < 0.001
RLL 0.67 < 0.001
LUL 0.92 < 0.001
LLL 0.89 < 0.001
RUL right upper lobe, RML right middle lobe, RLL right lower lobe, LUL left upper lobe, LLL left lower lobe, ICC
intraclass correlation coefficient
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Effective radiation dose and cancer risk estimation
The mean volume computed tomography dose index (CTDIvol)
values in standard- and low-dose groups were 13.115 ± 2.48 and
3.505 ± 0.83 mGy, respectively (P value < 0.001). The mean
DLP values were 412.810 ± 91.68 and 112.230 ±
26.55 mGy∙cm in standard- and low-dose groups, respectively.
The mean effective dose values in standard- and low-dose
groups were 6.60 ± 1.47 and 1.80 ± 0.42 mSv, respectively.
Absolute cancer risk per mean cumulative effective dose values
obtained from the standard- and low-dose CT examinations were
2.71 × 10−4 and 0.74 × 10−4, respectively (Table 3).
Discussion
Although recent studies have reported that chest CT has high
sensitivity in the detection of COVID-19 pneumonia [9–11],
characteristic radiologic features should be present in chest
CT of the patients, and the utilization of CT is still limited in
the era of COVID-19 pandemic. Current American College of
Radiology (ACR) guidelines state that CT should not be used
as a first-line test to screen and diagnosis of COVID-19 pneu-
monia [15] with nonspecific appearance of COVID-19 pneu-
monia on CT, associated radiation exposure and issues related
to infection control after using the imaging equipment, being
among the major reasons. Nevertheless, chest CTmay be used
in hospitalized symptomatic patients with relevant indications.
An updated CT imaging algorithm seems warranted in each
radiology department to maximize radiation protection and
achieve the ALARA radiation dose.
Medical imaging remains as one of the major sources of
radiation exposure in the USA. It has been proven that upward
trending of radiation increases the risk of malignancies [30].
Number and dose of CT studies are one of the largest sources
of imaging exposure. It is critical to make the maximum
Fig. 2 a, b Chest CT scan of a 53-year-old man with COVID-19 pneu-
monia. a Standard-dose image; a peripheral patch of ground glass opacity
with consolidation is seen in the posterior basal segment of the right lower
lobe. b Low-dose image at the same level; the lesion can be clearly
visible. The lesion was scored 2 (definitely present) by all the readers,
both on standard- and low-dose CT scans
Fig. 1 a, bChest CT scan of a 66-year-oldmanwithCOVID-19 pneumonia.
a Standard-dose image; a peripheral patch of ground glass opacity is seen in
the anterior segment of the right upper lobe. b Low-dose image at the same
level; the lesion is clearly visible. The lesion was scored 2 (definitely present)
by all the readers, both on standard- and low-dose CT scans
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efforts to utilize CT examinations with reduced radiation dose
without harm to diagnostic accuracy.
The purpose of our study was to determine whether it is
scientifically logical to accept a 30-mAs chest CT protocol as
an available routine protocol for COVID-19 pneumonia, a
pandemic condition which may necessitate multiple CT im-
aging for detection of suspicious indeterminate cases (e.g.,
negative RT-PCR with high clinical suspicion or definite his-
tory of exposure) and worsening of clinical findings in the
course of disease. Our results show that there is no significant
difference between the low-dose and standard-dose CT im-
ages in diagnosing radiographically normal laboratory-
confirmed COVID-19 pneumonia cases, with excellent agree-
ment rate among the readers. We showed that recently de-
scribed typical findings to suggest COVID-19 pneumonia on
chest CT can be evaluated appropriately using a low-dose CT
protocol (Figs. 1a,b, 2a,b, and 3a,b). In the same line, final
diagnosis of COVID-19 pneumonia on low-dose CT chest
was not affected in any of our twenty patients who had a
confirmed positive RT-PCR test. Of note, in our study the
mean CTDIvol, DLP, effective patients’ dose, and estimated
cancer risk were reduced by more than 73% without
sacrificing the diagnostic accuracy of the disease.
Chest CT scanning parameters applied for the diagnosis
of COVID-19 pneumonia in multiple recent studies have
been summarized in Table 4.
Multiple prior studies have confirmed that low-dose chest
CT protocols have a diagnostic accuracy similar to standard-
dose in spite of degraded image quality. A comprehensive
study performed by Kubo et al. demonstrated that low-dose
and standard-dose have statistically the same capability in
detection of intrathoracic abnormalities. More specifically,
their study demonstrated that low-dose chest CT (50 mAs) is
as accurate as standard-dose (150 mAs) in detection of pul-
monary parenchymal abnormalities (ground glass opacities,
emphysema, micronodules, honeycombing, and reticular den-
sities) and mediastinal/pleural findings (aortic aneurysm, cor-
onary arterial calcification, pleural effusion, lymphadenopa-
thy, and mediastinal tumors) [22]. Other studies have exam-
ined low-dose capability in CT pulmonary angiography [37].
Lung cancer screening programs with low-dose chest CT pro-
tocols have been associated with reduced mortality [38].
However, there is no current accepted low-dose protocol for
routine chest CT in selected clinical scenarios, like COVID-19
pneumonia.
It is worth mentioning that we evaluated chest CT scans of
20 patients with confirmed COVID-19 infection who had nor-
mal chest radiographs. This indicates that low-dose CT was
able to trace a type of disease which was radiographically
hidden. It is realistically clear that more diffuse disease on
chest radiographs will be even more feasible to be detected
on low-dose CT protocols. The identified lesions were all
typical for COVID-19 pneumonia as described in multiple
prior studies, and the most common lobes involved were
RLL and LLL, followed by the upper lobes, with the RML
being the less involved lobe, same as the prior studies [8–13].
Fig. 3 a, b Chest CT scan of a 51-year-old woman with COVID-19 pneu-
monia. a Standard-dose image; some patchy and linear consolidations are
seen in both lower lobes. b Low-dose image at the same level; the lesions
are clearly visible. The lesions were scored 2 (definitely present) by all the
readers, both on standard- and low-dose CT scans
Table 3 Data of radiation dose
and absolute cancer risk resulted
from standard-dose and low-dose
chest CT scan protocols in detec-
tion of COVID-19 pneumonia
Protocol type CTDIvol
(mGy)






Standard-dose 13.115 ± 2.48 412.81 ± 91.68 0.016 6.60 2.71
Low-dose 3.505 ± 0.83 112.23 ± 26.55 0.016 1.80 0.74
CTDIvol volume CT dose index, DLP dose-length product
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Although there were differences in scoring lobar involve-
ment between low-dose and standard-dose in some cases for
all three radiologists (intrareader), this did not affect the final
diagnosis of COVID-19 pneumonia in any case. This indi-
cates a 100% sensitivity for low-dose chest CT scan, consid-
ering standard-dose as the gold standard test. However, a larg-
er number of cases are required for estimating more accurate
sensitivity. Of note, ethical issues in obtaining two CT scans
and associated increased radiation exposure in such studies are
existent challenges.
Chest CT scan is normally performed in deep inspiration with
breath-hold status, but sometimes respiratory motion during the
scan can blur the images. The source of some mismatches be-
tween low-dose and standard-dose CT scans was the loss of
image quality due to the patient’s respiratory movements so that
depending on whether the motion artifact was in standard- or
low-dose, this may upgrade or downgrade the diagnostic score
in low-dose CT scan (Fig. 4a, b). The same concept is accurate
for matching image slices between low-dose and standard-dose.
Although in all of our 20 patients, the low-dose CT was done
immediately after the standard-dose, and the patient did notmove
on the CT table; in some cases the location of the imaging slices
in low-dose was not exactly the same as standard-dose. This
would affect the appearance of some small lesions on the second
CT scan creating a potential for interpretation mismatches.
Another limitation to our study is lack of objective standard for
abnormal findings. For a descriptive abnormality like GGOs, it is
hard to establish a gold standard among all the readers.
Conclusion
There was no statistically significant difference identified be-
tween the low-dose and standard-dose CT images in detecting
radiographically normal laboratory-confirmed COVID-19
pneumonia. Simultaneously, the low-dose protocol in our
study was associated with approximately 73% reduction in
mean effective dose value and estimated cancer risk.
Fig. 4 a, b Chest CT scan of a 63-year-old man with COVID-19 pneu-
monia. a Standard-dose image; peripheral patch of ground glass opacity is
seen in both lower lobes. The lesions were scored 2 by all readers. b Low-
dose image at the same level; the lesion in LLL was scored 1 (unclear/
equivocal) by two readers and 2 by the other. RLL lesion was scored 1 by
one reader and 2 by two readers. Note that the motion artifact due to
respiratory movements has blurred the lesions
Table 4 Chest CT scanning
parameters applied for the
diagnosis of COVID-19 in the
literature
Study kVp mAs Pitch factor Slice thickness CTDIvol
Caruso et al. [31] 120 100–250 0.98 1.25 –
Wen et al. [32] 120 145–300 – 2–3 9.34 ± 4.13
Yang et al. [12] 120 350 1 1.5 –
Pan et al. [33] 120 – – 1.5 8.4 ± 2.0
Liu et al. [34] 120 – – 1.5 4.1 ± 0.9
Song et al. [35] 120 180–400 1.5 5 –
Wang et al. [36] 120 320 1–1.5 1–5 –
Current study 120 150 (standard-dose)
30 (low-dose)
1 3 13.115 ± 2.48
(standard-dose)
3.505 ± 0.83 (low-dose)
kVp peak kilovoltage, mAs milliampere-seconds, CTDIvol volume CT dose index
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According to our findings, it was found that proposed low-
dose CT chest protocol is reliable in detecting COVID-19
pneumonia in daily practice with a significant reduction in
radiation dose and estimated cancer risk.
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Main points
1. In this prospective study, there is no significant difference between the
low-dose and standard-dose CT images in diagnosing radiographically
normal laboratory-confirmed COVID19 pneumonia cases, with excel-
lent agreement rate among the readers.
2. The mean CTDIvol, DLP, effective patients’ dose, and estimated can-
cer risk were reduced by more than seventy-three percent in the low-
dose group, without sacrificing the diagnostic accuracy of detecting
COVID-19 pneumonia.
3. Although there were differences in scoring lobar involvement between
the low-dose and standard-dose for the readers, this did not affect the
final diagnosis of COVID-19 pneumonia in any case, indicating a
100% sensitivity for the low-dose chest CT scan, considering a
standard-dose CT as the gold standard test.
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